NXNan Xu

Nan Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nan Xu has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Dongxian Zhou

    Shenzhen People's Hospital, Shenzhen 518020, China

    2 shared publications
  • Amr H. Abdelhamid Ahmed

    Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology‐Head and Neck Surgery, Massachusetts Eye and Ear Harvard Medical School Boston Massachusetts USA

    1 shared publication
  • Bin Han

    Department of Thyroid and Breast Surgery, Peking University Shenzhen Hospital, Shenzhen, China

    1 shared publication
  • Bo Wang

    Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology‐Head and Neck Surgery, Massachusetts Eye and Ear Harvard Medical School Boston Massachusetts USA

    1 shared publication
  • Chao Wang

    Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, China

    1 shared publication
  • Feng Mu

    MGI, BGI-Shenzhen, Shenzhen 518083, China

    1 shared publication

Latest Publications

  • Open Access

    Learning curve and functional safety in robotic thyroidectomy via bilateral axillo-breast approach: a prospective study of 537 cases

    by Si-Si Wang, Zi-Han Tang, Wen-Yu Huang, Xuan Lin, Shao-Feng He, Meng-Ting Lin, Nan Xu, Bin Han, ZhiHong Wang, Sean Hua, et al.

    Aim Robotic thyroidectomy via the bilateral axillo-breast approach (BABA) provides excellent cosmetic outcomes, but its adoption is limited by a steep learning curve and concerns about functional safety. This study aimed to define the learning curve trajectory and evaluate functional safety outcomes—with the primary endpoint of intraoperative RLN adverse events and secondary endpoints of inadvertent parathyroidectomy and PTH recovery. Methods A prospective cohort study was conducted at a high-volume endocrine surgery center from March 2018 to March 2024. A total of 537 consecutive patients with differentiated thyroid carcinoma underwent robotic BABA thyroidectomy with central neck dissection. Intraoperative refinements included real-time recurrent laryngeal nerve (RLN) monitoring, intraoperative parathyroid-hormone (PTH) testing, and nanocarbon lymph node mapping. Learning phases were defined by cumulative sum analysis. Primary outcomes were intraoperative RLN adverse events and inadvertent parathyroidectomy; secondary outcomes included operative time, lymph node yield, PTH recovery, complication rates, and tracheal injury. Results Among 537 patients (401 women, 74.7%; median age 43 years), operative time decreased from 189.9 to 129.3 min (P < 0.001), with plateaus at 152 and 352 cases. RLN adverse events declined from 16.7% (95% CI 7.9–30.2%) to 1.6% (95% CI 0.3–4.8%), and inadvertent parathyroidectomy decreased from 23.8% (95% CI 12.0–39.5%) to 1.6% (95% CI 0.3–4.8%). Six-month PTH levels improved from 3.15 to 4.14 pmol/L, and lymph node yield increased from 9.9 to 13.3 (P = 0.019). Three patients (0.6%) developed tracheal fistula. Conclusions Robotic BABA thyroidectomy demonstrates a structured learning curve in which functional safety improves with surgical experience and intraoperative standardization. These data-driven milestones may inform structured training and credentialing frameworks for robotic thyroid surgery.


  • Open Access

    A case-control study on the association of mineral elements exposure and thyroid tumor and goiter

    by Mei Liu, Jiayi Song, Yousheng Jiang, Yuan Liu, Jinling Peng, Huiwen Liang, Chao Wang, Jie Jiang, Xinjie Liu, Wei Wei, et al.


  • Open Access

    Plasma extracellular vesicle‑packaged microRNAs as candidate diagnostic biomarkers for early‑stage breast cancer

    by Chen Yan, Jintao Hu, Yipeng Yang, Hong Hu, Dongxian Zhou, Min Ma, Nan Xu

    Extracellular vesicle‑packaged microRNAs (miRNAs) are a class of circulating miRNAs located in the plasma that are packaged into extracellular vesicles. The present study examined the expression profiles of extracellular vesicles and tissue miRNAs with the aim of investigating the miRNA signatures in early‑stage breast cancer. The present study identified and compared the extracellular vesicle‑packaged miRNA expression signature and tissue miRNA expression signature from healthy individuals (n=10) and patients with early‑stage breast cancer (n=12). A total of five miRNAs, including miRNA‑375, miRNA‑24‑2‑5p, miRNA‑548b‑5p, miRNA‑655‑3P and miRNA‑376b‑5p, were synchronized in extracellular vesicles and tissues of the breast cancer group when compared with the healthy group. The highest area under the curve (AUC) for a single miRNA was achieved with miRNA‑548b‑5p [AUC=0.785; 95% confidence interval (CI)=0.585‑0.984; P=0.022]. The highest overall AUC was achieved by the combination of miRNA‑375, miRNA‑655‑3p, miRNA‑548b‑5p and miRNA‑24‑2‑5p (AUC=0.808; 95% CI=0.629‑0.986; P=0.013). The Kaplan‑Meier curves and log test analysis results of these five miRNAs, especially those for miRNA‑548b‑5p, were partly consistent with the hypothesis. Two miRNAs (miRNA‑548b‑5p and miRNA‑376b‑5p) were positively associated with patient survival, while two miRNAs (miRNA‑375 and miRNA‑24‑2‑5p) were negatively associated with patient survival. The present study provided a set of plasma extracellular vesicle‑packaged miRNA‑based biomarkers for the diagnosis of early‑stage breast cancer.


  • Detection of inherited mutations for hereditary cancer using target enrichment and next generation sequencing

    by Yanfang Guan, Hong Hu, Yin Peng, Yuhua Gong, Yuting Yi, Libin Shao, Tengfei Liu, Gairui Li, Rongjiao Wang, Pingping Dai, et al.

    Hereditary cancers occur because of inherited gene mutations. Genetic testing has been approved to provide information for risk assessment and rationale for appropriate intervention. Testing methods currently available for clinical use have some limitations, including sensitivity and testing throughput, etc. Next generation sequencing (NGS) has been rapidly evolving to increase testing sensitivity and throughput. It can be potentially used to identify inherited mutation in clinical diagnostic setting. Here we develop an effective method employing target enrichment and NGS platform to detect common as well as rare mutations for all common hereditary cancers in a single assay. Single base substitution across 115 hereditary cancer related genes using YH (the first Asian genome) was characterized to validate our method. Sensitivity, specificity and accuracy of 93.66, 99.98 and 99.97 %, were achieved, respectively. In addition, we correctly identified 53 SNVs and indels of BRCA1 and BRCA2 in two breast cancer specimens, all confirmed by Sanger sequencing. Accuracy in detecting copy number variation (CNV) was corroborated in 4 breast cancer specimens with known CNVs in BRAC1. Application of the method to 85 clinical cases revealed 22 deleterious mutations, 11 of which were novel. In summary, our studies demonstrate that the target enrichment combined with NGS method provides the accuracy, sensitivity, and high throughput for genetic testing for patients with high risk of hereditary or familial cancer.